Absci vs Korsana Biosciences
Absci is the larger business, with $2.8m of revenue in fiscal 2025 against $2.1m for Korsana Biosciences (1.4 times as much). Korsana Biosciences grew faster (3.7% against -38.2%). Korsana Biosciences kept more of each dollar of sales as profit: a net margin of -170.1% against -4113.7%. Korsana Biosciences carries less debt relative to equity (0.0% against 0.5%).
| Latest fiscal year | AbsciABSI, 2025 | Korsana BiosciencesKRSA, 2025 |
|---|---|---|
| Revenue | $2.8m | $2.1m |
| Revenue growth | -38.2% | 3.7% |
| Net income | −$115m | −$3.5m |
| Operating margin | -4297.0% | -239.8% |
| Net margin | -4113.7% | -170.1% |
| Return on equity | -62.5% | -39.3% |
| Free cash flow | −$94.0m | −$3.3m |
| Cash | $20.0m | $3.2m |
| Total debt | $873,000 | $0 |
| Debt to equity | 0.5% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 140 | — |
| Market value | $1.57bn | $138m |
| Price vs our value range | — | — |
| Moat score | 12 (Weak) | — |
| Insider trades, 12 months | 5 buys, 2 sales | 0 buys, 0 sales |